JP2015501822A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501822A5
JP2015501822A5 JP2014546468A JP2014546468A JP2015501822A5 JP 2015501822 A5 JP2015501822 A5 JP 2015501822A5 JP 2014546468 A JP2014546468 A JP 2014546468A JP 2014546468 A JP2014546468 A JP 2014546468A JP 2015501822 A5 JP2015501822 A5 JP 2015501822A5
Authority
JP
Japan
Prior art keywords
lipocalin mutein
pharmaceutical composition
mutein
composition according
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014546468A
Other languages
English (en)
Japanese (ja)
Other versions
JP6305345B2 (ja
JP2015501822A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/075135 external-priority patent/WO2013087654A2/en
Publication of JP2015501822A publication Critical patent/JP2015501822A/ja
Publication of JP2015501822A5 publication Critical patent/JP2015501822A5/ja
Application granted granted Critical
Publication of JP6305345B2 publication Critical patent/JP6305345B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014546468A 2011-12-12 2012-12-12 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法 Expired - Fee Related JP6305345B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161569501P 2011-12-12 2011-12-12
US61/569,501 2011-12-12
US201261599152P 2012-02-15 2012-02-15
US61/599,152 2012-02-15
PCT/EP2012/075135 WO2013087654A2 (en) 2011-12-12 2012-12-12 Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018039343A Division JP2018118980A (ja) 2011-12-12 2018-03-06 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法

Publications (3)

Publication Number Publication Date
JP2015501822A JP2015501822A (ja) 2015-01-19
JP2015501822A5 true JP2015501822A5 (enExample) 2016-02-04
JP6305345B2 JP6305345B2 (ja) 2018-04-04

Family

ID=47552958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014546468A Expired - Fee Related JP6305345B2 (ja) 2011-12-12 2012-12-12 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法
JP2018039343A Pending JP2018118980A (ja) 2011-12-12 2018-03-06 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018039343A Pending JP2018118980A (ja) 2011-12-12 2018-03-06 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法

Country Status (9)

Country Link
US (3) US9610356B2 (enExample)
EP (2) EP2791684B1 (enExample)
JP (2) JP6305345B2 (enExample)
CN (1) CN103998937A (enExample)
AU (1) AU2012350654C1 (enExample)
CA (1) CA2858959A1 (enExample)
DK (1) DK2791684T3 (enExample)
SG (2) SG11201402996WA (enExample)
WO (1) WO2013087654A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105168209A (zh) * 2015-09-21 2015-12-23 浙江大学 HDAC1抑制剂在制备调控hepcidin表达药物中的应用
CN105726543A (zh) * 2016-02-22 2016-07-06 浙江大学 腺嘌呤在制备调控hepcidin表达药物中的应用
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
CN109641954A (zh) * 2016-08-29 2019-04-16 里珍纳龙药品有限公司 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
CN113939307A (zh) 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
JP2023117892A (ja) * 2022-02-14 2023-08-24 公益財団法人 鷹揚郷 ヘプシジン結合ペプチド

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
EP1996613B1 (en) * 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
EP2498096A1 (en) 2006-07-21 2012-09-12 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
PE20130588A1 (es) 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
PE20091261A1 (es) 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
EP2803675A3 (en) 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
UA103032C2 (uk) 2008-08-06 2013-09-10 Елі Ліллі Енд Компані Селективні антитіла проти гепсидину-25 та їх застосування
EP2330897A4 (en) * 2008-09-18 2013-11-27 Univ Columbia NGAL-BINDING SIDEROPHORES AND THEIR USE FOR THE TREATMENT OF IRON DEFICIENCY AND IRON SURPLUS
CN103755808B (zh) * 2009-03-25 2016-02-10 霍夫曼-拉罗奇有限公司 抗-α5β1抗体及其应用
US9684002B2 (en) * 2010-05-10 2017-06-20 Intrinsic Lifesciences Llc Markers for acute kidney injury
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ngalタンパク質変異体及びその使用
AU2011290751B2 (en) * 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin

Similar Documents

Publication Publication Date Title
JP7544932B2 (ja) 抗体含有製剤
JP6305345B2 (ja) 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法
US20250109183A1 (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
Xiao et al. Lipocalin 2: an emerging player in iron homeostasis and inflammation
ES2424242T3 (es) Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
JP7395479B2 (ja) 免疫抑制なしにil-6媒介性炎症を処置する方法
EP4272838A2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
JP2010518079A5 (enExample)
JP2014519484A (ja) TNFR:Fc融合タンパク質の安定した医薬液剤
KR102416078B1 (ko) 항체 함유 제제
EP3452076A1 (en) Methods, regimens, combinations & antagonists
JP2017524675A5 (enExample)
JP2020518658A (ja) 癌治療用ペプチド
JP7697959B2 (ja) Il-2タンパク質とcd80タンパク質を含む融合タンパク質製剤
HK40121340A (en) Antibody-containing preparation
JP6578546B2 (ja) Lt阻害4価ペプチドおよびetec感染症治療薬